Goldman Ismail Secures Another Zantac Victory for GSK

On August 5, 2024, Goldman Ismail secured a second victory for GlaxoSmithKline after a Chicago jury found Zantac not responsible for an Illinois woman's illness. Partners Shayna Cook, Rami Fakhouri, Betsy Farrington handled key witnesses for GSK at trial, and Shayna delivered both the opening and the closing arguments.

As Reuters highlighted, “the only previous [Zantac] case to go to trial ended with a verdict in favor of GSK and Boehringer Ingelheim in May.” Goldman Ismail represented GSK in both recent victories. In a statement obtained by the Chicago Sun-Times, GSK explained that "the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.”

The Goldman Ismail team (Shayna Cook, Rami Fakhouri, Betsy Farrington, and Sarah Simon) partnered with co-counsel (Will Sachse and Rachel Leary of Dechert LLP, along with Tom Sheehan of Shook Hardy & Bacon LLP) to secure the victory for GSK. to secure the victory for GSK.

Press coverage is available here.